A novel cell therapy is safe and effective in patients with drug-resistant mesial temporal lobe epilepsy and could eventually offer an alternative intervention.

BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)-- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport” or the "Company”), a clinical-stage biotechnology company dedicated to the discovery and ...

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in ...

Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies. Lead ...

UCB has agreed to acquire U.S.-based Neurona Therapeutics for up to $1.15 billion to enhance its epilepsy portfolio. The transaction includes $650 million upfront and up to $500 million tied to future ...

TEMPORAL lobe epilepsy could be better controlled by enhancing the activity of a key neuronal transporter, according to new research showing that boosting potassium–chloride cotransporter 2 (KCC2) ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Temporal Technologies Inc., a startup with a cloud platform that makes artificial intelligence agents more reliable, has closed a $300 million funding round. Andreessen Horowitz led the Series D ...

Localization of the epileptogenic zone to extratemporal regions—specifically perisylvian and frontal lobes—is strongly associated with an increased risk for sudden unexpected death in epilepsy.

A new study suggests temporal lobe epilepsy may be linked to early aging of certain brain cells. When researchers removed these aging cells in mice, seizures dropped, memory improved, and some animals ...

Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...